New directions for emerging therapies in acute myeloid leukemia: the next chapter

[1]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[2]  J. Cortes,et al.  Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. , 2020 .

[3]  J. Novak,et al.  A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update. , 2020 .

[4]  M. Konopleva,et al.  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.

[5]  J. Novak,et al.  Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. , 2020, Blood.

[6]  J. Taub,et al.  Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia , 2020, Signal transduction and targeted therapy.

[7]  High Risk Myelodysplastic Syndrome , 2020, Definitions.

[8]  Austin E. Gillen,et al.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. , 2020, Cancer discovery.

[9]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[10]  S. Choe,et al.  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. , 2019, Blood.

[11]  A. Wei,et al.  New drugs creating new challenges in acute myeloid leukemia , 2019, Genes, chromosomes & cancer.

[12]  R. Varadhan,et al.  Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients , 2019, Blood.

[13]  A. Letai,et al.  Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies , 2019, Blood.

[14]  H. Döhner,et al.  Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study , 2019, Blood.

[15]  Xiaomei Ma,et al.  Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States , 2019, Blood.

[16]  M. Konopleva,et al.  Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2019, Blood.

[17]  H. Kantarjian,et al.  Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida) , 2019, Blood.

[18]  M. Konopleva,et al.  Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy , 2019, Blood.

[19]  D. Small,et al.  Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM , 2019, Blood.

[20]  P. Vyas,et al.  High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine , 2019, Blood.

[21]  M. Konopleva,et al.  IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML) , 2019, Blood.

[22]  Wan-Jen Hong,et al.  Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study , 2019, Blood.

[23]  H. Einsele,et al.  Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. , 2019, Blood.

[24]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[25]  Xiaoyan Liu,et al.  Isocitrate dehydrogenase inhibitors in acute myeloid leukemia , 2019, Biomarker Research.

[26]  D. Pollyea,et al.  How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia , 2019, Leukemia.

[27]  Yongping Song,et al.  Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia , 2019, Biomarker Research.

[28]  P. Balasubramanian,et al.  A personalized approach to acute myeloid leukemia therapy: current options , 2019, Pharmacogenomics and personalized medicine.

[29]  C. Dinardo,et al.  Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions , 2019, Current Hematologic Malignancy Reports.

[30]  N. Daver,et al.  From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia , 2019, Drugs.

[31]  H. Dombret,et al.  Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[32]  M. Bally,et al.  Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia , 2019, Pharmaceutical Research.

[33]  M. Konopleva,et al.  Venetoclax-based therapies for acute myeloid leukemia. , 2019, Best practice & research. Clinical haematology.

[34]  R. Walter,et al.  Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come? , 2019, Current Hematologic Malignancy Reports.

[35]  E. Estey,et al.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.

[36]  R. Collins,et al.  Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia , 2019, Leukemia.

[37]  Fang Zhou,et al.  Quizartinib (AC220): a promising option for acute myeloid leukemia , 2019, Drug design, development and therapy.

[38]  A. Wei,et al.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[40]  R. Schlenk,et al.  Targeting FLT3 mutations in AML: review of current knowledge and evidence , 2019, Leukemia.

[41]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[42]  C. Dinardo,et al.  Advances in patient care through increasingly individualized therapy , 2019, Nature Reviews Clinical Oncology.

[43]  P. Sharma,et al.  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.

[44]  Fang Zhou,et al.  Quizartinib (AC220): a promising option for acute myeloid leukemia , 2019, Drug design, development and therapy.

[45]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[47]  M. Heuser,et al.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[48]  Jiang Liu,et al.  FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[49]  P. Ellis,et al.  The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity , 2018, Blood.

[50]  M. Belvin,et al.  Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents , 2018, Blood.

[51]  J. Esteve,et al.  Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort , 2018, Blood.

[52]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[53]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[54]  Sean P. Brown,et al.  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. , 2018, Cancer discovery.

[55]  F. Colland,et al.  Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia , 2018, Leukemia.

[56]  H. Dombret,et al.  Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial , 2018, Haematologica.

[57]  N. Daver,et al.  Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. , 2018, The American journal of managed care.

[58]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Estey,et al.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[60]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[61]  A. Fathi,et al.  Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML , 2018, OncoTargets and therapy.

[62]  M. Konopleva,et al.  Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia , 2018, American journal of hematology.

[63]  C. Dinardo,et al.  The role of IDH mutations in acute myeloid leukemia. , 2018, Future oncology.

[64]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[65]  Marina Konopleva,et al.  Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. , 2017, Cancer cell.

[66]  R. Mesa,et al.  Combined venetoclax and alvocidib in acute myeloid leukemia , 2017, Oncotarget.

[67]  M. Konopleva,et al.  Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia , 2017, International journal of molecular sciences.

[68]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[69]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[70]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[71]  A. Fathi,et al.  The role of FLT3 inhibitors in the treatment of FLT3‐mutated acute myeloid leukemia , 2017, European journal of haematology.

[72]  M. Konopleva,et al.  Frontline treatment of acute myeloid leukemia in adults. , 2017, Critical reviews in oncology/hematology.

[73]  C. Preudhomme,et al.  Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists , 2016, Expert review of hematology.

[74]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[75]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[76]  Catherine J. Wu,et al.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.

[77]  S. Wander,et al.  Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. , 2015, Seminars in hematology.

[78]  P. Söderkvist,et al.  TP53 mutations and MDM2SNP309 identify subgroups of AML patients with impaired outcome , 2015, European journal of haematology.

[79]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[80]  M. Konopleva,et al.  The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial , 2014 .

[81]  E. Estey,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.

[82]  M. Levis,et al.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond , 2014, Therapeutic advances in hematology.

[83]  Jorge Cortes,et al.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. , 2013, Blood.

[84]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[85]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Kantarjian,et al.  Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. , 2010, Leukemia research.

[87]  R. Verhaak,et al.  Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. , 2010, Cancer treatment and research.

[88]  R. Hills,et al.  Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial. , 2007 .

[89]  E. Estey,et al.  Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. , 2007, Blood.

[90]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[91]  B. Esterni,et al.  Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia , 2007, Cancer.

[92]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[93]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[94]  E. Estey,et al.  Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. , 2005 .

[95]  A. Delmer,et al.  Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period , 1999, Leukemia.

[96]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.